Novo Nordisk A/S (NVO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
NVO's revenue distribution by segment and geography
By Geography
NVO Revenue Analysis (2014–2025)
As of March 1, 2026, Novo Nordisk A/S (NVO) generated trailing twelve-month (TTM) revenue of $297.20 billion, reflecting significant decline in growth of -21.5% year-over-year. The most recent quarter (Q4 2025) recorded $67.28 billion in revenue, down 10.3% sequentially.
Looking at the longer-term picture, NVO's 5-year compound annual growth rate (CAGR) stands at +18.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $297.20 billion in 2025, representing a new all-time high.
When compared to Healthcare sector peers including ABBV (+7.4% YoY), AMGN (+9.9% YoY), and GILD (+2.4% YoY), NVO has underperformed the peer group in terms of revenue growth. Compare NVO vs ABBV →
Peer Comparison
Compare NVO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NVOCurrent | $297.2B | -21.5% | +18.5% | 41.4% | |
| ABBV | $56.3B | +7.4% | +11.1% | 16.2% | |
| AMGN | $36.8B | +9.9% | +7.6% | 40.5% | |
| GILD | $28.8B | +2.4% | +5.1% | 5.8% | |
| BIIB | $9.8B | +1.4% | -6.1% | 19.1% | |
| SCLX | $57M | -26.8% | - | -147.4% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $297.20B | +2.3% | $240.66B | 81.0% | $123.04B | 41.4% |
| 2024 | $290.40B | +25.0% | $245.88B | 84.7% | $128.34B | 44.2% |
| 2023 | $232.26B | +31.3% | $196.50B | 84.6% | $102.57B | 44.2% |
| 2022 | $176.95B | +25.7% | $148.51B | 83.9% | $74.81B | 42.3% |
| 2021 | $140.80B | +10.9% | $117.14B | 83.2% | $58.64B | 41.7% |
| 2020 | $126.95B | +4.0% | $106.01B | 83.5% | $54.13B | 42.6% |
| 2019 | $122.02B | +9.1% | $101.93B | 83.5% | $52.48B | 43.0% |
| 2018 | $111.83B | +0.1% | $94.21B | 84.2% | $47.25B | 42.2% |
| 2017 | $111.70B | -0.1% | $94.06B | 84.2% | $48.97B | 43.8% |
| 2016 | $111.78B | +3.6% | $94.60B | 84.6% | $48.43B | 43.3% |
See NVO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NVO vs AGIO
See how NVO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NVO's revenue growth accelerating or slowing?
NVO revenue declined -21.5% year-over-year, contrasting with the 5-year CAGR of +18.5%. TTM revenue fell to $297.2B. This reverses the prior growth trend.
What is NVO's long-term revenue growth rate?
Novo Nordisk A/S's 5-year revenue CAGR of +18.5% reflects the variable expansion pattern. Current YoY growth of -21.5% is below this long-term average.
How is NVO's revenue distributed by segment?
NVO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.